Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02634320 · ClinicalTrials.gov registry record · Phase 4
A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia
A Phase 4 study, sponsored by Alkermes.
- Completed
- Registry status
- Phase 4
- Development phase
- 51
- Enrollment target
NCT02634320 is a Phase 4 study that has completed, run by Alkermes. The registered enrollment target is 51 participants.
The verdict
NCT02634320, a Phase 4 study, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 51 participants
- Enrollment target
Study Summary
This study will evaluate the safety and tolerability of aripiprazole lauroxil (also known as ARISTADA, ALKS 9070).
Interventions
- DRUG Aripiprazole Lauroxil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2015-12 |
| Est. Completion | 2017-07-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02634320
The ClinicalTrials.gov registry entry for NCT02634320 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alkermes, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aripiprazole Lauroxil is the first listed.
NCT02634320 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02634320 about?
NCT02634320 is a clinical study titled "A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia". This study will evaluate the safety and tolerability of aripiprazole lauroxil (also known as ARISTADA, ALKS 9070).
What is the current status of trial NCT02634320?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 51 participants. The study started on 2015-12. Estimated completion is 2017-07-11.
What interventions are being tested in trial NCT02634320?
The interventions under investigation include: Aripiprazole Lauroxil (DRUG).
Who is sponsoring clinical trial NCT02634320?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.